Financial insights of BRNS

MyFinsight

For the year ending 2025-12-31.

Income Statement	2025-12-31
Total revenue	0
Research and development	25,564,000
General and administrative	40,830,000
Impairment of intangible assets	4,667,000
Goodwill impairment	0
Total operating expenses	71,061,000
Other operating income	506,000
Loss from operations	-70,555,000
Interest income	1,957,000
Interest expense	51,000
Research and development incentives	2,000,000
Other income	16,000
Total other income, net	3,922,000
Loss before income tax	-66,633,000
Tax benefit	-175,000
Net loss	-66,458,000
Net loss attributable to noncontrolling interest	-30,000
Net loss attributable to barinthus biotherapeutics plc shareholders	-66,428,000

Basic EPS	-1.64
Diluted EPS	-1.64
Basic Average Shares	40,527,218
Diluted Average Shares	40,527,218